Related references
Note: Only part of the references are listed.Children and young adults with CF in the USA have better lung function compared with the UK
Christopher H. Goss et al.
THORAX (2015)
Accelerating implementation of biomedical research advances: critical elements of a successful 10 year Cystic Fibrosis Foundation healthcare delivery improvement initiative
Bruce C. Marshall et al.
BMJ QUALITY & SAFETY (2014)
Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)
Edward F. McKone et al.
LANCET RESPIRATORY MEDICINE (2014)
Modifying disease in cystic fibrosis: current and future therapies on the horizon
Thida Ong et al.
CURRENT OPINION IN PULMONARY MEDICINE (2013)
Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial
Jane Davies et al.
LANCET RESPIRATORY MEDICINE (2013)
Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations
Philip H. Quanjer et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
Risk factors for rate of decline in FEV1 in adults with cystic fibrosis
Michael W. Konstan et al.
JOURNAL OF CYSTIC FIBROSIS (2012)
Growth failure in children with cystic fibrosis
Alessandra Scaparrotta et al.
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM (2012)
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Bonnie W. Ramsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clinical Use of Dornase Alfa Is Associated With a Slower Rate of FEV1 Decline in Cystic Fibrosis
Michael W. Konstan et al.
PEDIATRIC PULMONOLOGY (2011)
Propensity Score Methods
Donald B. Rubin
AMERICAN JOURNAL OF OPHTHALMOLOGY (2010)
Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint
M. W. Konstan et al.
JOURNAL OF CYSTIC FIBROSIS (2010)
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003
Peter C. Austin
STATISTICS IN MEDICINE (2008)
Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis
Michael W. Konstan et al.
JOURNAL OF PEDIATRICS (2007)
Clinical trial participants compared with nonparticipants in cystic fibrosis
CH Goss et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study
EF McKone et al.
LANCET (2003)
Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project
G Steinkamp et al.
THORAX (2002)
Predictors of deterioration of lung function in cystic fibrosis
C Schaedel et al.
PEDIATRIC PULMONOLOGY (2002)
Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients
MD Schluchter et al.
STATISTICS IN MEDICINE (2002)
A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities
JM Quan et al.
JOURNAL OF PEDIATRICS (2001)
Share Paper
